2nd Annual Hawaii Cancer Conference

Breakfast

Welcome, Introductions, and Presession Survey

Session 1A: Screening/Early Detection and Application of (Neo)Adjuvant Therapy in Stage I-III NSCLC

Session 1B: Combined Modality Therapy Including Radiotherapy and Targeted Agents in Locally Advanced NSCLC

Session 2A: Molecular Testing Tumor Board in Advanced NSCLC: How to Interpret Test Results and Choose Treatment

Session 2B: Treatment of Advanced/Metastatic NSCLC With Classical EGFR Mutations

Session 2C: ALK and ROS1 in NSCLC: From Early-Stage Adjuvant to Advanced-Stage, 5-Year OS

Session 3A: First-Line Immunotherapy in Advanced/Metastatic NSCLC

Session 3B: Other Novel Therapies: Emerging Role of ADCs in NSCLC

Session 4: Treatment of SCLC: New Options From Limited to Extensive Stage

Session 5: Joint Session (Lung and Breast Cancer): Management of Adverse Events From ADCs

Session 1A: MRD Testing: Ready for Primetime? Perspectives from Breast and Lung Cancer

Session 1B: Current Standards for Early-Stage TNBC

Session 1C: Changing Algorithms for Metastatic TNBC

Session 2A: Rightsizing (Neo)Adjuvant Treatment for HER2+ Early Breast Cancer

Session 2B: Optimizing Treatment for HER2+ Advanced/Metastatic Breast Cancer

Session 3A: New Approaches for ESR1-Mutated HR+/HER2- MBC

Session 3B: Managing High-Risk Early-Stage HR+/HER2- Breast Cancer

Session 3C: Targeting PI3K/AKT in HR+ MBC

Session 3D: Antibody-Drug Conjugates for Endocrine-Resistant HR+/HER2- MBC